Changes in Hong Kong stocks | Jinhai Medical Technology (02225) rose more than 20%, and the cumulative increase after entering the market was nearly 60%, and the minimally invasive medical business surged more than threefold year-on-year in the first half of the year

The Zhitong Finance App learned that Jinhai Medical Technology (02225) rose more than 20% in the intraday period, with a cumulative increase of nearly 60% after entering the market. As of press release, it rose 15.18% to HK$6.6, with a turnover of HK$81.3857 million.

According to the news, recently, Jinhai Medical Technology was officially included in the Hong Kong Stock Connect list. This inclusion has opened up a compliant purchase channel for southbound capital, further improving stock liquidity. In the first half of 2026, the share of revenue from minimally invasive surgery solutions, medical products and related service fees climbed to 74.73%. Following a good increase in medical device sales revenue in 2025, the business's revenue surged 301.5% year-on-year in the first half of the year to reach SG$25.427 million, with sufficient momentum for sustainable growth. The explosive growth of the minimally invasive surgery solutions business has verified the company's solid skills in product development and manufacturing.

It is important to note that behind the increase in performance is the company's long-term deep cultivation and continuous breakthroughs in technology research and development. According to information, Jinhai Medical Technology's product matrix has covered a series of innovative products such as 4K ultra-high definition endoscopy systems, 3D and naked eye 3D image processing systems, 4K fluorescence and multi-spectral ultra-high definition endoscopy systems, and 8K endoscopy systems, and extended to supporting auxiliary equipment, forming a closed loop in the entire industry chain from R&D, production to sales and service.